Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (November 2020)
15 slides from Arovella Therapeutics's investor presentation, Nov 17, 2020
Slide 1: Investor Presentation
ACN 090 987 250 ASX Release Investor Presentation PERTH, AUSTRALIA – 17 November 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Michael Baker is presenting at the Finance News Network Virtual Investor Event on 17 November, 2020. A cop
Slide 2: About SUDA Pharmaceuticals Ltd
NOTES TO EDITORS: About SUDA Pharmaceuticals Ltd SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharm
Slide 3: Finance News Network Virtual Investor Event
Finance News Network Virtual Investor Event Dr Michael Baker November 2020 © Copyright SUDA Pharmaceuticals Ltd 2020
Slide 4: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of SUDA PHARMACEUTICALS LTD (ASX:SUD) [‘SUDA’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slid
Slide 5: Company Highlights
Company Highlights Focus – Oncology and CNS ▪ Refreshed Board and Management Team: Actively seeking new deal flow for technologies with a focus on oncology and the central nervous system ▪ Unique Platform Technology – OroMist™: Reformulate existing billion-dollar drugs for oral delivery, faster path
Slide 6: Technology Highlights - OroMist
Technology Highlights - OroMist™ ▪ Clinical Data1 Demonstrates: ▪ Increased Bioavailability The most effective drug dosing methods ▪ The drug bypasses the gastro-intestinal tract preventing breakdown so patient’s can potentially take less drug ▪ Faster onset of action: Bioavailability (% absorbed) ▪
Slide 7: IP & Platform Strategy
IP & Platform Strategy INTELLECTUAL PROPERTY ▪ Multiple patent families covering: ▪ Many high-usage existing drugs formulated into oral sprays ▪ Hydrotrope technology for better delivery of drugs across the oral mucosa ▪ Anagrelide use in cancer – granted in Europe, Japan and Australia ▪ We will con
Slide 8: Pharmaceutical Partnership Strategy
Pharmaceutical Partnership Strategy 6 © Copyright SUDA Pharmaceuticals Ltd 2020
Slide 9: Business Strategy - Develop and License
Business Strategy - Develop and License License Internal Sales Drug Regulatory Development Feasibility Preclinical Clinical trials Approved (royalties) Submissions ZolpiMist (insomnia) Sumatriptan (migraine) Medical Grade Target Assets Cannabis Undisclosed Anagrelide (solid tumours) Value 7 © Copyri
Slide 10: ZolpiMist - Insomnia
ZolpiMist - Insomnia ▪ ZolpiMist is SUDA’s spray version of the insomnia drug Ambien - Sanofi’s blockbuster insomnia treatment ▪ Licensed territories covering 550 million people ▪ SUDA has rest-of-world rights ex-North America1, and has licensed the product to Teva and Mitsubishi Tanabe Pharma Singa
Slide 11: Anagrelide - Reformulating to Treat Cancer
Anagrelide - Reformulating to Treat Cancer ▪ Anagrelide: An approved generic drug to treat a rare blood disorder ▪ Research Shows: Cancer patients with high platelet counts have a poor prognosis and lowering platelets may increase survival rates ▪ Making Anagrelide Safer: The capsule has unwanted si
Slide 12: Expanding our Portfolio
Expanding our Portfolio ▪ SUDA has a refreshed board and senior management team ▪ The team has expertise in sourcing, evaluating and acquiring novel technologies ▪ SUDA’s key areas of focus are oncology and the central nervous system ▪ SUDA will continue to source deal flow and add new technologies
Slide 13: Board & Senior Management
Board & Senior Management Chairman CEO & Managing Director Executive Director Director Paul Hopper Dr. Michael Baker David Phillips David Simmonds Over 25 years experience in the Over 15 years experience in scientific Senior Business Development Executive David was a Senior Audit Partner with medica
Slide 14: Strategic Future
Strategic Future ▪ Source, Evaluate and Acquire new technologies ▪ Continue to expand the team with deep Biotechnology/Drug Development/Pharma experience ▪ Build out the intellectual property portfolio – patents and knowhow ▪ Build out the OroMist platform to reformulate existing billion-dollar drug
Slide 15: Contact
CONTACT Dr Michael Baker The CFO Solution CEO & Managing Director Level 3 Email: mbaker@sudapharma.com 62 Lygon Street Mobile: +61 403 468 187 Carlton VIC 3053 (T) +61 8 6142 5555 (F) +61 8 9443 8858 © Copyright SUDA Pharmaceuticals Ltd 2020
Arovella Therapeutics — Investor Presentation (November 2020) on 6ix